Loading...
| Jan 01, 1970 | Daily Report |
| RISING BHARAT | News Count (103064) | |
20591. Panacea Biotec gets regulator’s nod to produce Sputnik V jabs
India Fights Corona: Vaccination Drive and Initiatives
English
India
Mint
|
- Panacea Biotec has received a licence from the Drugs Controller General for manufacturing the Sputnik V vaccine in India, after the first batch of the covid-19 vaccine cleared all quality-control tests at the Gamaleya Center, Russia, the company said
- Panacea tied up with Russian Direct Investment Fund (RDIF) to produce the vaccine developed by Gamaleya Research Institute of Epidemiology and Microbiology.
- The first batch of Sputnik V, manufactured at Panacea Biotec’s Baddi facility in Himachal Pradesh, passed quality control checks at the Gamaleya Center in Russia and the Central Drugs Laboratory, Kasauli.
20592. Indian scientists working on developing new vaccine technology get grant
India Fights Corona: Vaccination Drive and Initiatives
English
India
Mint
|
- Ignite Life Science Foundation has awarded its first grant award for "pandemic preparedness" research to a team of researchers at the Indian Institute of Science (Bengaluru) and the Translational Health Science and Technology Institute (Faridabad).
- The grant, will support the research by them for developing for the first time in India the technology platform and reagents required to design, make and test novel mRNA vaccines, ILSF said.
- The grant will be for three years and will fund research to develop the platform technologies for mRNA vaccine development.
20593. कोवीशील्ड के सामने कोरोना बेदम:दोनों डोज के बाद कोरोना होने की आशंका को 93% कम करती है कोवीशील्ड, सशस्त्र बलों पर दुनिया की सबसे बड़ी स्टडी का नतीजा
India Fights Corona: Vaccination Drive and Initiatives
Hindi
India
Dainik Bhaskar
|
- देश के सशस्त्र बलों पर हुई स्टडी के मुताबिक कोवीशील्ड के दोनों डोज लेने के बाद होने वाला कोरोना यानी Breakthrough Infection 93% कम पाया गया है।
- आर्म्ड फोर्सेज मेडिकल कॉलेज (AFMC) की यह स्टडी दुनिया में अब तक की सबसे बड़ी स्टडी है, जिसका सैंपल साइज 15 लाख से भी अधिक है ।
- महाराष्ट्र में मेडिकल एजुकेशन एंड रिसर्च के डायरेक्टर के मुताबिक कोरोना की वजह से अस्पताल में भर्ती होने वाले 87.5 प्रतिशत लोग अनवैक्सीनेटेड थे ।
20594. कोविशील्ड की दोनों डोज में बढ़ाए गैप का एस्ट्राजेनेका ने किया समर्थन, कहा- इससे अधिक होगा फायदा
Make in India / Atmanirbhar
->
Make in India- Public Health and Infrastructure
English
India
One India
|
- भारत में लगाई जा रही कोविशील्ड वैक्सीन के दोनों डोज के अंतराल में अभी तक चार बार बदलाव किया जा चुका है।
- इस बीच ब्रिटिश फार्मा कंपनी एस्ट्राजेनेका ने कोविशील्ड की दो डोज में किए गए गैप का समर्थन किया है।
- कंपनी ने कहा है कि इस वैक्सीन की सिंगल डोज लगने के बाद दूसरी डोज अगर तीन महीने बाद लगती है तो ये ज्यादा सुरक्षा प्रदान करती है।
20595. Vaccine boost: Covaxin for children above 2 years by September, says AIIMS chief
Make in India / Atmanirbhar
->
Make in India- Public Health and Infrastructure
English
India
India Today
|
- The leading pulmonologist and crucial member of the government's task force on Covid-19 told India Today TV that Covaxin's data for children after completion of the Phase 2/3 trials will be available by September and the approval is expected same month.
- Delhi AIIMS has already started screening children for these trials. This started on June 7 and involves children between the age of 2 to 17.
- Guleria also said that policymakers must now look at opening up schools in a way that would prevent institutes from becoming super-spreader events. When asked about opening up schools, he said, “a holistic approach has to be taken.”
20596. Covaxin shows 77.8% efficacy in phase 3 trial data in review by SEC
Make in India / Atmanirbhar
->
Make in India- Public Health and Infrastructure
English
India
Hindustan Times
|
- The efficacy rate came out on Tuesday after DGCI's subject expert committee (SEC) met and discussed the results.
- The pharmaceutical firm had submitted phase 3 trial data for the vaccine to the Drug Controller General of India (DGCI) over the weekend.
- Covaxin has shown efficacy of 77.8% from trial conducted on 25,800 subjects, according to the data submitted.
20597. Pfizer CEO Albert Bourla says in final stages of reaching COVID-19 vaccine supply agreement with Indian govt
Make in India / Atmanirbhar
->
Make in India- Public Health and Infrastructure
English
India
Moneycontrol
|
- Bourla said that Pfizer will be able to produce 3 billion vaccines by the end of 2021, and 4 billion vaccines in 2022.
- Bourla said Pfizer has specific plans to meet the demand of COVID-19 vaccines for lower and middle income countries (LMIC) including India.
- Bourla said Pfizer recently concluded a deal with the US government, wherein US government purchases 500 million of COVID-19 doses at below the cost of production, and give to LMIC countries at free of cost.
20598. One dose of Covid vaccine 82% effective in preventing death, 2 doses 95% effective: ICMR-NIE study
Make in India / Atmanirbhar
->
Make in India- Public Health and Infrastructure
English
India
Indian Express
|
- A single dose of Covid 19 vaccine is effective in preventing deaths, according to a new analysis by the Indian Council of Medical Research-National Institute of Epidemiology (ICMR-NIE).
- The study ‘Covid-19 vaccine effectiveness in preventing deaths among high-risk groups in Tamil Nadu, India’, was published in the Indian Journal of Medical Research on June 21.
- The incidence of Covid-19 deaths among the vaccinated with zero, one and two doses was 1.17, 0.21 and 0.06 per 1,000 police personnel respectively.
20599. देश में पहली बार यहां पर लगाई गई 2 साल 8 महीने की बच्ची को वैक्सीन, ट्रायल में तीन आयु वर्ग के बच्चे शामिल
Make in India / Atmanirbhar
->
Make in India- Public Health and Infrastructure
English
India
Zee News
|
- उत्तर प्रदेश के कानपुर में स्वदेशी वैक्सीन कोवैक्सीन के पीडियाट्रिक ट्रायल के तहत सबसे कम उम्र 2 साल 8 महीने की बच्ची को वैक्सीन लगाई गई है.
- टीकाकरण कार्यक्रम में तीन लड़कियां दो लड़के शामिल थे. जिन्हें वैक्सीन लगाई गई उनका सेफ्टी प्रोफाइल तैयार किया जाएगा. अगली स्क्रीनिंग में 2 साल का बच्चा रहेगा जिसे टीका लगाया जाएगा.
- जिन बच्चों को ट्रायल में शामिल किया गया, उनकी आरटीपीसीआर (RTPCR) जांच कराई गई जो निगेटिव आई. वैक्सीन लगाने के पहले उनका ब्लड सैंपल लिया गया. इसे जांच के लिए आईसीएमआर दिल्ली भेजा गया है.
20600. Serum to Begin Trials of Covovax Vaccine on 920 Children, Will Seek Govt Nod Soon
Make in India / Atmanirbhar
->
Make in India- Public Health and Infrastructure
English
India
News18
|
- Serum Institute of India (SII) plans to begin phase 2 and 3 paediatric trials of Covovax on 920 children — 460 each in the 12-17 and 2-11 age groups.
- (SII) will apply for permission from the Drug Controller and General of India (DCGI) to conduct a clinical trial of Covovax- an Indian version of US-based Novavax Inc-developed on children.
- It will be the fourth Covid-19 vaccine to go through clinical trials in India, this time for children.